![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Promoting Use of Generics, Biosimilars Will Reduce Public Health Spending, EC Says
Promoting Use of Generics, Biosimilars Will Reduce Public Health Spending, EC Says
October 20, 2016
The European Commission is recommending that countries promote the use of generics and biosimilars to reduce healthcare spending.
A joint report from EC’s Economic Policy Committee and Aging Working Group suggests that encouraging the use of copycat products is one way the EU can save on drug spending.
Specifically, the report recommends that member states accelerate marketing authorization, pricing and reimbursement decisions on generics and biosimilars, noting that there are policies, such as the Directive 2001/83/EC, already in place to speed up approvals.
Upcoming Events
-
21Oct